Yuni Asri

58139309900

Publications - 3

Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023

Mohamad Amin Bakhshali Shoshana H. Ballew Ovidiu Constantin Baltatu Maciej Banach Mainak Bardhan Ahmed Abdelrahman Abdelgalil Saurav Basu Bekalu Mekonen Belay Makda Abate Belew Aminu K. Bello Luis Belo Amiel Nazer C. Bermudez Fahmi Y. Al-Ashwal Nurudeen A. Adegoke Nelson Alvis-Guzman Yaser Mohammed Al-Worafi Adel Sharaf Al-Zubairi Masoud Aman Mohammadi Hubert Amu Filippos Anagnostakis Abhishek Anil Sajjad Ahmad Neeraj Bedi Anayochukwu Edward Anyasodor Geminn Louis Carace Apostol Walter Appati Sulaimon O. Araromi Hiba Jawdat Barqawi Rizwan Suliankatchi Abdulkader Amir Mahmoud Ahmadzade Salah Al Awaidy Syed Shujait Ali Omar Almidani Hanadi Al Hamad Syed Mahfuz Al Hasan Karem H. Alzoubi Maha Moh'd Wahbi Atout Samar Abd ElHafeez Sajjad Ahmad Nesredin Ahmed Marjan Ajami Ayman Ahmed Yazan Al Thaher Salahdein Aburuz Ashagre Molla Assaye Khursheed Aurangzeb Adedapo Wasiu Awotidebe Domenico Azzolino Muhammad Badar Lucas Guimarães Abreu Qorinah Estiningtyas Sakilah Adnani Bright Opoku Ahinkorah Dmitry Abramov Bilyaminu Abubakar Olugbenga Olusola Abiodun Oyelola A. Adegboye Isaac Yeboah Addo Qorinah Estiningtyas Sakilah Adnani Hasan Aalruz Qorinah Estiningtyas Sakilah Adnani M. D.Abu Bashar Shahid Bashir Mohammad Mahdi Bastan Akshaya Srikanth Bhagavathula Sonu Bhaskar Ajay Nagesh Bhat Temitayo Esther Adeyeoluwa Johan Ärnlöv Bernard Kwadwo Yeboah Asiamah-Asare Syed Anees Ahmed Patrick B. Mark Lauryn K. Stafford Morgan E. Grams Hansani Madushika Abeywickrama Mohammed Mehdi Abrar Khabir Ahmad Hasan Aalruz Ali Ahmadi Aram Mahmood Ahmed Shahzaib Ahmed Priyadarshini Bhattacharjee Jasvinder Singh Bhatti Salahdein Aburuz Aleksandr Y. Aravkin Mohammed Z. Allouh Mohammadreza Akbari Oluwasefunmi Akeju Mohammed Ahmed Akkaif Ziyad Al-Aly Mohammed Albashtawy Shereen M. Aleidi Ali M. Alfalki Fadwa Naji Alhalaiqa Khalid A. Alhasan Endale Alemayehu Ali Rafat Ali Syed Yusuf Ali Samah W. Al-Jabi Mohammed Z. Allouh Wesam Taher Almagharbeh Maha Moh d.Wahbi Atout Khaldoon Aied Alnawafleh Najim Z. Alshahrani Awais Altaf Sadat Abdulla Aziz Jesu Arockiaraj Yuni Asri Sadat Abdulla Aziz Rizwan Suliankatchi Abdulkader

Publication Name: Lancet

Publication Date: 2025-11-22

Volume: 406

Issue: 10518

Page Range: 2461-2482

Description:

Background Chronic kidney disease (CKD) is common and ranks among the leading causes of mortality and morbidity. This analysis aimed to present global CKD estimates using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 to inform evidence-based policies for CKD identification and treatment. Methods This analysis focused on adults aged 20 years and older over the period 1990 to 2023, from 204 countries and territories. Data sources used were published literature, vital registration systems, kidney failure treatment registries, and household surveys. Estimates of CKD burden, including deaths, incidence, prevalence, and disability-adjusted life-years (DALYs), were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool. A comparative risk assessment approach estimated the proportion of cardiovascular deaths attributable to impaired kidney function and estimated risk factors for CKD. Findings Globally, in 2023, 788 million (95% uncertainty interval 743–843) people aged 20 years and older were estimated to have CKD, up from 378 million (354–407) in 1990. The global age-standardised prevalence of CKD in adults was 14·2% (13·4–15·2), a relative rise of 3·5% (2·7–4·1) from 1990. The region with the highest age-standardised prevalence was north Africa and the Middle East (18·0%; 16·9–19·4). Most people had stage 1–3 CKD, with a combined prevalence of 13·9% (13·1–15·0). In 2023, CKD was the ninth leading cause of death globally, accounting for 1·48 million (1·30–1·65) deaths, and the 12th leading cause of DALYs, with an age-standardised DALY rate of 769·2 (691·8–857·4) per 100 000. Impaired kidney function as a risk factor accounted for 11·5% (8·4–14·5) of cardiovascular deaths. High fasting plasma glucose, body-mass index, and systolic blood pressure were all leading risk factors for CKD DALYs. Interpretation CKD is a major global health issue, with rising prevalence and increasing importance as a cause of death and as a risk factor for cardiovascular death. A better understating of aetiology, appropriate screening, and implementation programmes are needed to translate advances in CKD treatment into improved patient outcomes. Funding Gates Foundation, Wellcome, US National Kidney Foundation, and US National Institute of Diabetes and Digestive and Kidney Diseases.

Open Access: Yes

DOI: 10.1016/S0140-6736(25)01853-7

Disease burden attributable to intimate partner violence against females and sexual violence against children in 204 countries and territories, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Amani Alansari Rana Kamal Abu Farha Haroon Ahmed Muayyad M. Ahmad Aanuoluwapo Adeyimika Afolabi Kamoru Ademola Adedokun Nurudeen A. Adegoke Lisa C. Adams Armita Abedi Mesfin Abebe Hubert Amu Anayochukwu Edward Anyasodor Aqeel Ahmad Williams Agyemang-Duah Mohmmad Minwer Alnaeem Muhammad Sohail Afzal Danish Ahmad Alemwork Abie Rotimi Felix Afolabi Saira Afzal Seyyed Shamsadin Athari Samar Abd ElHafeez Mehrunnisha Sharif Ahmed Ayman Ahmed Meriem Abdoun Zufishan Alam Lucas Guimarães Abreu Qorinah Estiningtyas Sakilah Adnani Bright Opoku Ahinkorah Haroon Ahmed Bilyaminu Abubakar Sawsan Abuhammad Meshack Achore Roberto Ariel Abeldaño Zuñiga Asma Ahmed Hasan Aalruz Olumide Abiodun Richard Gyan Aboagye Habeeb Omoponle Adewuyi Leticia Akua Adzigbli M. D.Abu Bashar Shahid Bashir Mohammad Mahdi Bastan Oluwatobi E. Adegbile Olumide Thomas Adeleke Miracle Ayomikun Adesina Hasan Aalruz Aleksandr Y. Aravkin Roberto Ariel Abeldaño Zuñiga Melaku Birhanu Alemu Hamid Alinejad Rokny Md Al-Mamun Joseph Uy Almazan Mohmmad Minwer Alnaeem Mohammad Sharif Ibrahim Alyahya Tarek Tawfik Amin Saeed Amini Sohrab Amiri Luisa S. Flor Jimoh Amzat Cory N. Spencer Jack Cagney Montaha Al-Iede Intima Alrimawi Saeid Anvari David B. Anderson Tahira Ashraf Boluwatife Stephen Anuoluwa Julie Alaere Atta Wondu Feyisa Balcha Gabriela Fernanda Gil Siddig Ibrahim Abdelwahab Yonas Abebe Babatope Oluwadamilare Adebiyi Jorge Arias de la Torre Benedetta Armocida Alejandra Arrieta Deepavalli Arumuganainar Shereen M. Aleidi Makinde Adebayo Adeniyi Fadwa Naji Alhalaiqa Oli Ahmed Bilal Aslam Prince Atorkey Elizabeth Oluwatoyin Akin-Odanye Wole Akosile Idorenyin Ubon Akpabio Rasmieh Mustafa Al-Amer Turki M. Alanzi Asma Ahmed Sachin R. Atre Abadi Hailay Atsbaha Madhu Sudhan Atteraya Ahmed Y. Azzam B. Sheeba Khlood K. Baghlaf Atif Amin Baig Jose Balmori-de-la-Miyar Soham Bandyopadhyay Manish Barik Suzanne Lyn Barker-Collo Wesam Taher Almagharbeh Azadeh Bashiri Najim Z. Alshahrani Yuni Asri Asma Ahmed

Publication Name: Lancet

Publication Date: 2026-01-03

Volume: 407

Issue: 10523

Page Range: 31-52

Description:

Background Violence against women and against children are human rights violations with lasting harms to survivors and societies at large. Intimate partner violence (IPV) and sexual violence against children (SVAC) are two major forms of such abuse. Despite their wide-reaching effects on individual and community health, these risk factors have not been adequately prioritised as key drivers of global health burden. Comprehensive x§and reliable estimates of the comparative health burden of IPV and SVAC are urgently needed to inform investments in prevention and support for survivors at both national and global levels. Methods We estimated the prevalence and attributable burden of IPV among females and SVAC among males and females for 204 countries and territories, by age and sex, from 1990 to 2023, as part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2023. We searched several global databases for data on self-reported exposure to IPV and SVAC and undertook a systematic review to identify the health outcomes associated with each of these risk factors. We modelled IPV and SVAC prevalence using spatiotemporal Gaussian process regression, applying data adjustments to account for measurement heterogeneity. We employed burden-of-proof methodology to estimate relative risks for outcomes associated with IPV and SVAC. These estimates informed the calculation of population attributable fractions, which were then used to quantify disability-adjusted life-years (DALYs) attributable to each risk factor. Findings Globally, in 2023, we estimated that 608 million (95% uncertainty interval 518–724) females aged 15 years and older had ever been exposed to IPV, and 1·01 billion (0·764–1·48) individuals aged 15 years and older had experienced sexual violence during childhood. 18·5 million (8·74–30·0) DALYs were attributed to IPV among females and 32·2 million (16·4–52·5) DALYs were attributed to SVAC among males and females in 2023. IPV and SVAC were among the top contributors to the global disease burden in 2023, particularly among females aged 15–49 years, ranking as the fourth and fifth leading risk factors, respectively, for DALYs in this group. Among the eight health outcomes found to be associated with IPV, anxiety disorders and major depressive disorder were the leading causes of IPV-attributed DALYs, accounting for 5·43 million (–1·25 to 14·6) and 3·96 million (1·71 to 6·92) DALYs in 2023, respectively. SVAC was associated with 14 health outcomes, including mental health disorder, substance use disorder, and chronic and infectious disease outcomes. Self-harm and schizophrenia were the leading causes of SVAC-attributed burden, with SVAC accounting for 6·71 million (2·00 to 12·7) DALYs due to self-harm and 4·15 million (–1·92 to 13·1) DALYs due to schizophrenia in 2023. Interpretation IPV and SVAC are substantial contributors to global health burden, and their health consequences span a variety of individual health outcomes. Importantly, mental health disorders account for the greatest share of disease burden among survivors. Investing in prevention of these avoidable risk factors has the potential to avert millions of DALYs and considerable premature mortality each year. Our findings represent strong evidence for global and national leaders to elevate IPV and SVAC among public health priorities. Sustained investments are needed to prevent IPV and SVAC and to implement interventions focused on supporting the complex social and health needs of survivors. Funding Gates Foundation.

Open Access: Yes

DOI: 10.1016/S0140-6736(25)02503-6

Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Mohammad Fareed Giridhara Rathnaiah Babu Shankar M. Bakkannavar Anurag Agrawal Mahaveer Golechha Jesu Arockiaraj Devananda Devegowda Atif Amin Baig Rupesh K. Gautam Ferry Efendi Mahwish Arooj Vijay Kumar Chattu Ripon Kumar Adhikary Narayan Babu Dhital Anup Bhat Dinh Toi Chu Ashish D. Badiye Tahira Ashraf Ibrahim Elsohaby Saurav Basu Ayesha Fahim Syed Amir Ashraf Jaeyu Park Syed Shujait Ali Sheikh Mohammad Alif Jeetendra Bhandari Arun Ghuge Ahmad Naoras Bitar Mohammad Shahangir Biswas Linh Phuong Bui Bijit Biswas Syed Mahfuz Al Hasan Awais Altaf Zahid A. Butt Danish Ahmad Min Seo Kim Khurshid Alam Jeffrey Shi Kai Chan Muthia Cenderadewi Ginenus Fekadu Bibha Dhungel Narasimha M. Beeraka Muhammad Abdul Basit Ashraf Ildar Ravisovich Fakhradiyev Rafat Ali Qorinah Estiningtyas Sakilah Adnani Niroj Bhandari Balasubramanian Ganesh Tauseef Ahmad Syed Mohamed Aljunid Biswajit Banik Samath Dhamminda Dharmaratne Hitesh Chopra Siddhartha Dutta Sumbul Ansari Sajjad Ahmad An Tian Chen Anil Raj Assariparambil Sirshendu Chaudhuri Arushee Bhatnagar Mohammed Ahmed Akkaif Naveed Ahmed Syed Mohammed Basheeruddin Asdaq Mohammed Usman Ali Mainak Bardhan Ajay Nagesh Bhat Khabir Ahmad Sreedhar Dharmagadda Chiranjib Chakraborty Yuni Asri Sridevi G Artyom Urievich Gil Amol S. Dhane Priyadarshini Bhattacharjee Xueting Ding Jiyeon Oh Syed Yusuf Ali Thao Huynh Phuong Do Shehab Uddin Al Abid Tae Hyeon Kim Sandip Chakraborty Hyesu Jo Haiyan Chen Sunghyun Chung Ojas Prakashbhai Doshi Xiang Gao Kabilan Annadurai Nurila Aryntayeva Qorinah Estiningtyas Sakilah Adnani Samiun Nazrin Bente Kamal Tune Md Al-Mamun Aram Mahmood Ahmed Huyen Phuc Do Vinoth Gnana Chellaiyan Devanbu Syed Anees Ahmed Haroon Ahmed Guodong Ding MD Faisal Ahmed Syed Mohamed Aljunid Zareen Fatima Nadeem Shafique Butt Syed Masudur Rahman Dewan

Publication Name: Lancet Respiratory Medicine

Publication Date: 2026-03-01

Volume: 14

Issue: 3

Page Range: 233-255

Description:

Background: Chronic respiratory diseases are an important global issue, particularly in Asia, where burden patterns vary widely across countries. With more than half the world's population living in Asia, understanding the national and regional burden of chronic respiratory diseases is essential; however, research on this area remains inadequate. We aimed to investigate the burden of chronic respiratory diseases in Asia at national and regional levels, and to identify key risk factors. Methods: The Global Burden of Diseases, Injuries, and Risk Factors Study 2023 provides estimates for assessing the burden of chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, pneumoconiosis, interstitial lung disease (ILD), and pulmonary sarcoidosis. We focused on 34 countries in Asia, encompassing the high-income Asia Pacific region and central, east, south, and southeast Asia. Estimates for age-standardised prevalence and disability-adjusted life-year (DALY) rates per 100 000 population, including 95% uncertainty intervals (UIs), were extracted by location, sex, year, and Socio-demographic Index (SDI). The average annual percentage change was calculated and presented as a percentage with 95% CIs. Estimates of modifiable attributable risk factors for DALYs and mortality were also included. Findings: In Asia, the age-standardised prevalence and DALY rates for chronic respiratory diseases generally declined from 1990 to 2023; however, the trend varied substantially by disease and country. In 2023, the age-standardised prevalence rate of COPD was highest in south Asia (3044·18 [95% UI 2748·67–3303·04] per 100 000 population), while the age-standardised asthma prevalence rate was highest in the high-income Asia Pacific region (4870·24 [4046·70–5962·78] per 100 000 population) and southeast Asia (4778·18 [3970·25–5735·61] per 100 000 population). Despite southeast Asia and the high-income Asia Pacific region having a similar age-standardised asthma prevalence rate, southeast Asia had a higher age-standardised DALY rate (508·67 [95% UI 394·89–669·92] per 100 000 population) compared with the high-income Asia Pacific region (204·40 [129·23–290·41] per 100 000 population). A decrease in the age-standardised DALY rate for chronic respiratory diseases was observed with increasing SDI, contrasting with its prevalence patterns. Age-standardised DALY rates of COPD decreased in all Asian countries except for Georgia (average annual percentage change 1·37 [95% CI 1·26–1·48]) and Kazakhstan (0·73 [0·55–0·93]), and age-standardised DALY rates of asthma decreased in all countries. Smoking and ambient particulate matter pollution were identified as leading attributable risk factors for chronic respiratory diseases across Asia. Household air pollution from solid fuels was a regionally pronounced risk factor for chronic respiratory diseases, particularly in south Asia (age-standardised DALY rate 657·58 [95% UI 485·04–880·45] per 100 000 population). Although smoking was a major risk factor in males, ambient particulate matter pollution and secondhand smoke emerged as important attributable risk factors for chronic respiratory diseases in females. Interpretation: Countries with lower SDI had markedly higher DALY rates, highlighting the need to address socioeconomic and health-care inequities. Household air pollution from solid fuels continues to impose a substantial but preventable burden in south Asia, calling for clean energy adoption and improved ventilation. Funding: Gates Foundation.

Open Access: Yes

DOI: 10.1016/S2213-2600(25)00404-7